HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- (4- hydroxy- 2- methoxybenzylidene)anabaseine

Also Known As:

4OH-GTS-21

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Anabasine: 34
    - 3-(4-hydroxy-2-methoxybenzylidene)anabaseine: 4
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - Anabasine: 34
      - 3-(4-hydroxy-2-methoxybenzylidene)anabaseine: 4

Experts

1.	Gaidhani, Nikhil: 2 articles (01/2021 - 01/2021)
2.	Kem, William R: 2 articles (01/2021 - 01/2021)
3.	Uteshev, Victor V: 2 articles (01/2021 - 01/2021)
4.	Beaton, Graham: 1 article (01/2021)
5.	Tucci, Fabio C: 1 article (01/2021)
6.	Altman, M: 1 article (08/2007)
7.	Hughes, J A: 1 article (08/2007)
8.	King, M A: 1 article (08/2007)
9.	Liu, J: 1 article (08/2007)
10.	Meyer, E M: 1 article (08/2007)

Related Diseases

1.	Ischemic Stroke 01/01/2021 - "Here, we provide evidence that 4OH-GTS-21, a selective α7 agonist, produces its therapeutic effects via primarily central sites of action because 4OH-GTS-21 was found equally effective in splenectomized and non-spenectomized rats in the sub-acute phase of ischemic stroke (≤1 week). " 01/01/2021 - "Spleen is not required for therapeutic effects of 4OH-GTS-21, a selective α7 nAChR agonist, in the sub-acute phase of ischemic stroke in rats." 01/01/2021 - "This hypothesis was tested using a transient middle cerebral artery occlusion (MCAO) model of acute ischaemic stroke, NS6740, a known selective non-ionotropic agonist of α7 nAChRs and 4OH-GTS-21, a partial α7 agonist. "
2.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/01/2021 - "This hypothesis was tested using a transient middle cerebral artery occlusion (MCAO) model of acute ischaemic stroke, NS6740, a known selective non-ionotropic agonist of α7 nAChRs and 4OH-GTS-21, a partial α7 agonist. "
3.	Brain Injuries (Brain Injury) 01/01/2021 - "4OH-GTS-21, used as a positive control, significantly reduced neurological deficits and brain injury after MCAO as compared to vehicle and NS6740. "
4.	Atrophy 08/10/2007 - "injections of 1 mg/kg of 4OH-GTS-21 for 2 weeks promoted the survival and prevented the atrophy of septal cholinergic neurons. "
5.	Alzheimer Disease (Alzheimer's Disease) 06/01/2004 - "Two BA compounds with substituents at the 2 and 4 positions of the benzylidene ring, GTS-21 and 4OH-GTS-21, may have therapeutic potential for treating neuropathological disorders such as Alzheimer's disease due to their alpha 7 selectivity. "

Related Drugs and Biologics

1.	Therapeutic Uses
2.	1,4- diazabicyclo(3.2.2)nonan- 4- yl(5- (3- (trifluoromethyl)phenyl)furan- 2- yl)methanone
3.	3-(2,4-dimethoxybenzylidene)anabaseine

Related Therapies and Procedures

1.	Injections